EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients

Daniela Egli-Spichtig, Ahmad Kamal Hamid, Eva Maria Pastor Arroyo, Markus Ketteler, Andrzej Wiecek, Alexander R Rosenkranz, Andreas Pasch, Horst Lorenz, Burkhard Hellmann, Michael Karus, Richard Ammer, Isabel Rubio-Aliaga iD und 1 weitere

Clinical Kidney Journal · 29.09.2023 · 16 (10) · 1622-1633

DOI: 10.1093/ckj/sfad040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 10.03.2023. Verfasst von Daniela Egli-Spichtig und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physiology, University of Zurich, 8057 Zurich, Switzerland, and National Center of Competence in Research NCCR Kidney.CH. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperphosphatemia is associated with increased mortality and cardiovascular morbidity of end-stage kidney failure (ESKF) patients. Managing serum phosphate in ESKF patients is challenging and mostly based on limiting intestinal phosphate absorption with low phosphate diets and phosphate binders (PB). In a multi-centric, double-blinded, placebo-controlled study cohort of maintenance hemodialysis patients with hyperphosphatemia, we demonstrated the efficacy of nicotinamide modified release (NAMR) formulation treatment in addition to standard PB therapy in decreasing serum phosphate. Here we aimed to assess the relationship between phosphate, FGF23, inflammation and iron metabolism in this cohort.

Methods

We measured the plasma concentrations of intact fibroblast growth factor 23 (iFGF23) and selected proinflammatory cytokines at baseline and Week 12 after initiating treatment.

Results

We observed a strong correlation between iFGF23 and cFGF23 (C-terminal fragment plus iFGF23). We identified iFGF23 as a better predictor of changes in serum phosphate induced by NAMR and PB treatment compared with cFGF23. Recursive partitioning revealed at baseline and Week 12, that iFGF23 and cFGF23 together with T50 propensity were the most important predictors of serum phosphate, whereas intact parathyroid hormone (iPTH) played a minor role in this model. Furthermore, we found serum phosphate and iPTH as the best predictors of iFGF23 and cFGF23. Sex, age, body mass index, and markers of inflammation and iron metabolism had only a minor impact in predicting FGF23.

Conclusion

Lowering serum phosphate in ESKF patients may depend highly on iFGF23 which is correlated to cFGF23 levels. Serum phosphate was the most important predictor of plasma FGF23 in this ESKF cohort.

Schlagwörter

Stichwörter der Autor:innen

FGF23haemodialysishyperparathyroidisminflammationironphosphatemia

Autor:innen und Institutionen

  • Institute of Physiology, University of Zurich, 8057 Zurich, Switzerland, and National Center of Competence in Research NCCR Kidney.CH.
  • Robert Bosch Hospital, Department of General Internal Medicine and Nephrology, Stuttgart, Germany.
  • Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland.
  • Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Calciscon AG, 2503 Biel, Switzerland.
  • Department of Nephrology, Lindenhofspital, 3012 Bern, Switzerland.

ORCID-Profile: Isabel Rubio-Aliaga, Carsten A Wagner

Förderung

  • Swiss National Science Foundation

Zitieren

APA

Egli-Spichtig, D., Hamid, A. K., Arroyo, E. M. P., Ketteler, M., Wiecek, A., Rosenkranz, A. R., Pasch, A., Lorenz, H., Hellmann, B., Karus, M., Ammer, R., Rubio-Aliaga, I., & Wagner, C. A. (2023). Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients. Clinical Kidney Journal, 16(10), 1622-1633. https://doi.org/10.1093/ckj/sfad040

Vancouver

Egli-Spichtig D, Hamid AK, Arroyo EMP, Ketteler M, Wiecek A, Rosenkranz AR, et al. Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients. Clinical Kidney Journal. 2023;16(10):1622-1633. doi:10.1093/ckj/sfad040

BibTeX
@article{EgliSpichtig2023,
  author = {Egli-Spichtig, Daniela and Hamid, Ahmad Kamal and Arroyo, Eva Maria Pastor and Ketteler, Markus and Wiecek, Andrzej and Rosenkranz, Alexander R and Pasch, Andreas and Lorenz, Horst and Hellmann, Burkhard and Karus, Michael and Ammer, Richard and Rubio-Aliaga, Isabel and Wagner, Carsten A},
  title = {Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients},
  journal = {Clinical Kidney Journal},
  year = {2023},
  volume = {16},
  number = {10},
  pages = {1622--1633},
  doi = {10.1093/ckj/sfad040}
}
Kostenlos starten →